

DATA SUPPLEMENT

Intracranial Efficacy and Survival with Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2+ Breast Cancer with Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin, Virginia Borges, Carey Anders, Rashmi K. Murthy, Elisavet Paplomata, Erika Hamilton, Sara Hurvitz, Sherene Loi, Alicia Okines, Vandana Abramson, Philippe L. Bedard, Mafalda Oliveira, Volkmar Mueller, Amelia Zelnak, Michael P. DiGiovanna, Thomas Bachelot, A. Jo Chien, Ruth O'Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa Carey, Giuseppe Curigliano, Karen Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P. Winer

Supplemental Table 1. Intracranial Efficacy and Survival Per Investigator in Patients with Untreated Brain Lesions at Baseline

	Tuc+Tras+Cape (N=44)	Pbo+Tras+Cape (N=22)
Median CNS-PFS, months (95% CI)	8.1 (5.5, 11.6)	3.1 (1.4, 7.6)
Median OS, months (95% CI)	16.5 (12.4, NE)	11.2 (6.0, 19.9)
Confirmed Intracranial Objective Response Rate (ORR-IC),* % (n/N) (95% CI)	47.1 (8/17) (23.0, 72.2)	16.7 (1/6) (0.4, 64.1)

Abbreviations: TUC: tucatinib; Tras: trastuzumab; Cape: capecitabine.

* Includes only patients with measurable disease